RJA
NUVB icon

Raymond James & Associates’s Nuvation Bio NUVB Stock Holding History

Raymond James & Associates’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,710
Closed -$19.7K – 3910
2023
Q3 		$19.7K Sell
14,710
-3,000
-17% -$4.99K ﹤0.01% 3738
2023
Q2 		$31.9K Sell
17,710
-3,900
-18% -$6.63K ﹤0.01% 3741
2023
Q1 		$35.9K Buy
21,610
+600
+3% +$1.22K ﹤0.01% 3763
2022
Q4 		$40.3K Sell
21,010
-350
-2% -$708 ﹤0.01% 3736
2022
Q3 		$48K Hold
21,360
– – ﹤0.01% 3710
2022
Q2 		$69K Buy
21,360
+5,300
+33% +$23.1K ﹤0.01% 3746
2022
Q1 		$84K Buy
16,060
+3,600
+29% +$20.2K ﹤0.01% 3856
2021
Q4 		$106K Buy
12,460
+1,000
+9% +$9.19K ﹤0.01% 3852
2021
Q3 		$114K Buy
11,460
+500
+5% +$4.53K ﹤0.01% 3809
2021
Q2 		$102K Buy
+10,960
New +$125K ﹤0.01% 3833

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's NUVB Position: Q4 2023 in Review

Raymond James & Associates sold out of Nuvation Bio (NUVB) in Q4 2023, closing a stake of 14,710 shares — an estimated $19.7K sold.

Raymond James & Associates first reported a position in NUVB in Q2 2021 and held it in 10 quarters. The position peaked at $114K in Q3 2021. 116 funds tracked by Wall St. Rank hold NUVB as of Q4 2023.

  • Raymond James & Associates reported no remaining Nuvation Bio position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 14,710 Nuvation Bio shares in Q4 2023, an estimated $19.7K.
  • Raymond James & Associates first reported a position in Nuvation Bio in Q2 2021 and held it in 10 quarters.
  • Raymond James & Associates's Nuvation Bio position peaked at $114K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.